Outset Medical, Inc.·Healthcare

SAN JOSE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company's Inducement Plan, as a material inducement to employment to Derick Elliott, the Company's newly appointed Executive Vice President of Commercial, as well as one newly appointed non-executive employee, in each case, who were not previous employees or directors of the Company.

SAN JOSE, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced the appointment of Derick Elliott as Executive Vice President of Commercial, effective immediately.

Shares of Outset Medical, Inc. (NASDAQ: OM - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy

ZUG, Switzerland, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Binance has announced that the Digital Asset under the Certificates will be subject to a MANTRA (OM) token swap, redenomination and rebranding to MANTRA (MANTRA): OM tokens will assume the ticker of MANTRA tokens on Binance; All OM tokens will be swapped to MANTRA at a ratio of 1 OM = 4 MANTRA though a non-dilutive split; Implementation is currently expected to take effect on 2 March 2026; and Separately, a trading halt at Spotlight regarding the Certificates is expected to be imposed on 2 March and 3 March 2026 to ensure orderly fair and market conditions. Further information regarding the token swap, redenomination and rebranding is available at: https://www.binance.com/en/support/announcement/detail/4d13052b4be943f5b155cb9150ca902c?utm_source=new_share&ref=CPA_00Q01Y04QJ The Issuer hereby gives Holders notice that said events constitute a Transformation Event as defined in the Conditions applicable to the Certificates.

Shares of Outset Medical, Inc. (NASDAQ: OM - Get Free Report) have been given an average rating of "Moderate Buy" by the five research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy

Outset Medical, Inc. (OM) Q4 2025 Earnings Call Transcript
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Healthcare
Medical - Devices
354
2020-09-15
1.96